Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia
Psychopharmacology Bulletin · 12.08.2025 · 40 (1) · 57-62
DOI: 10.64719/pb.4131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmacology Bulletin, online erschienen am 12.08.2025. Verfasst von Vicki L. Ellingrod und 12 weiteren Autor:innen. Die Arbeit wurde bisher 9-mal zitiert (Crossref).
Abstract (Originalsprache)
Objective
The objective of the current investigation was to determine the relationship between polymorphisms of the leptin system (leptin gene and leptin receptor) and olanzapine-induced weight gain in persons with schizophrenia.
Design
Pharmacogenetic association reanalysis of a longitudinal, open-label, six-week, fixed-dose trial of olanzapine response and adverse effects. Subjects: Thirty-seven males and females with clinically symptomatic schizophrenia (age, 23–52) meeting DSM-IV criteria.
Measurements
Baseline and endpoint weight, BMI, olanzapine dose, plasma levels, and psychopathology measures were completed in a prior study. These subjects were subsequently genotyped for the –1548 G/A polymorphism of the leptin gene and the Q223R polymorphism of the leptin receptor. The relationship between alleles at each locus, olanzapine plasma levels, and percent change in body mass index (BMI) from baseline were conducted.
Results
Genotypes and alleles for each locus were not individually associated with olanzapine-induced weight gain in this study population. Changes in BMI from baseline increased significantly in persons with olanzapine plasma levels ≥20.6 ng/mL for subjects carrying at least one G allele at both candidate loci compared to those who did not have a G allele at each (P = 0.049).
Conclusions
This study suggests that genetic variability in the leptin gene and leptin receptor may predispose some individuals to excessive weight gain from increased exposure to olanzapine. Psychopharmacology Bulletin. 2007;40(1):57-62.
Zitieren
APA
Ellingrod, V. L., PharmD, BCPP, Bishop, J. R., PharmD, MS, Moline, J., BS, Lin, Y., MS, Miller, A. D. D., PharmD, & MD (2025). Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia. Psychopharmacology Bulletin, 40(1), 57-62. https://doi.org/10.64719/pb.4131
Vancouver
Ellingrod VL, PharmD, BCPP, Bishop JR, PharmD, MS, et al. Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia. Psychopharmacology Bulletin. 2025;40(1):57-62. doi:10.64719/pb.4131
BibTeX
@article{Ellingrod2025,
author = {Ellingrod, Vicki L. and PharmD and BCPP and Bishop, Jeffrey R. and PharmD and MS and Moline, Jessica and BS and Lin, Ying-Chi and MS and Miller, and Del D. and PharmD and MD},
title = {Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia},
journal = {Psychopharmacology Bulletin},
year = {2025},
volume = {40},
number = {1},
pages = {57--62},
doi = {10.64719/pb.4131}
}
EUVIMED